Literature DB >> 978042

Severe staphylococcal disease associated with allergic manifestations, hyperimmunoglobulinemia E, and defective neutrophil chemotaxis.

H R Hill, R D Estensen, N A Hogan, P G Quie.   

Abstract

Neutrophil granulocyte function was determined in three patients with systemic staphylococcal infection, clinical manifestations of generalized allergic disease, and hyperimmunoglobulinemia E. Each of the patients had urticarial skin rashes before or at the time of development of staphylococcal suppurative lymphadenitis, pneumonia, or sepsis. Neutrophil chemotaxis, random migration, phagocytosis, and bactericidal capacity were assessed to determine if an abnormality in these functions might have contributed to the development of severe staphylococcal infections. Each of the three patients with generalized urticaria was found to have a marked defect in neutrophil chemotaxis. The mean chemotactic index of the patients was 12 +/- 4, whereas that of 20 controls was 72 +/- 11. Neutrophil random migration, phagocytosis, and bactericidal capacity were normal in each patient. The serum or plasma of the patients did not inhibit chemotaxis of control neutrophils and did not contain an increased concentration of the chemotactic-factor inactivator found in normal serum. Treatment of the neutrophils of these three patients with the competitive histamine H2 receptor blocking agent, burimamide, produced a significant increase in chemotactic responsiveness. These studies suggest the possibility of pharmacologic modification of neutrophil granulocyte function.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 978042

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  13 in total

Review 1.  The molecular pathology of primary immunodeficiencies.

Authors:  Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2004-05       Impact factor: 5.568

2.  Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect.

Authors:  E C Moore; F Cohen; S D Douglas; V Gutta
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 3.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

4.  Functional defects of neutrophils in visceral larva migrans syndrome.

Authors:  G Maggiore; F Sacchi; M Marconi; E Bianchi; A D Cas; A G Siccardi
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  Mononuclear cells from patients with the hyperimmunoglobulin E-recurrent infection syndrome produce an inhibitor of leukocyte chemotaxis.

Authors:  H Donabedian; J I Gallin
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

6.  A child with atopic features, raised serum IgE, and recurrent infection treated with levamisole.

Authors:  L Businco; F Laurenti; P Rossi; E Galli; F Aiuti
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

7.  Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children.

Authors:  A Condino-Neto; M M Vilela; E C Cambiucci; J D Ribeiro; A A Guglielmi; L A Magna; G De Nucci
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

8.  Effects of aminoglycoside antibiotics on neutrophil chemotaxis.

Authors:  F Sacchi; G Marseglia; A Fietta; A Marchi; A G Siccardi
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

9.  Contrasting disease patterns in psoriasis and atopic dermatitis.

Authors:  E Christophers; T Henseler
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

10.  [The Buckley syndrome: recurring, severe staphylococcal infections, eczema and hyperimmunoglobulinemia E. (author's transl)].

Authors:  S Däumling; D Buriot; P H Trung; C Griscelli; M C Lalama; B H Belohradsky
Journal:  Infection       Date:  1980       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.